Literature DB >> 16236941

Advanced age does not exclude lobectomy for non-small cell lung carcinoma.

Vita Sullivan1, Tao Tran, Amy Holmstrom, Michael Kuskowski, Paul Koh, Jeffrey B Rubins, Rosemary F Kelly.   

Abstract

STUDY
OBJECTIVES: Localized non-small cell lung carcinoma (NSCLC) is best treated by complete surgical resection, commonly requiring lobectomy. The impact of lobectomy on the health status of the elderly patient is not well-characterized. The aim of this study was to compare the effect of lobectomy in elderly patients (> or = 70 years of age) and younger patients (< 70 years of age) on their pulmonary function and functional status 1 year following surgery.
DESIGN: One hundred forty patients underwent lobectomy for NSCLC at the Minneapolis Veterans Affairs Medical Center from January 1999 to December 2003. All patients underwent pulmonary function tests (PFTs) and functional status assessment using Karnofsky scores (KS) that were assessed preoperatively. Sixty-three of 140 lobectomy patients were available 1 year postoperatively for reevaluation by PFTs and KS.
RESULTS: There was no statistical difference between groups in either the pulmonary function or functional status testing results at 1 year after undergoing lobectomy. FVC decreased by 14% in the elderly patient and by 9% in the younger patient group. FEV1 decreased by 19% in elderly patients and by 13% in younger patients. Functional status declined for two older patients (8%), who dropped their KS from 80 to 100% (normal activity without limitation) to 40 to 70% (unable to work, but able to care of self at home). Nine of the younger patients (24%) had KS drop from 80 to 100% to 40 to 70%. There was one perioperative death (30-day mortality rate for the study groups, 1.5%).
CONCLUSIONS: Elderly patients > or = 70 years of age undergoing lobectomy for NSCLC had similar PFT results and functional status as younger patients < 70 years of age 1 year after undergoing surgery. Curative resection should not be denied based on age alone.

Entities:  

Mesh:

Year:  2005        PMID: 16236941     DOI: 10.1378/chest.128.4.2671

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Outcome of VATS Lobectomy for Elderly Non-Small Cell Lung Cancer: A Propensity Score-Matched Study.

Authors:  Xizhao Sui; Hui Zhao; Jun Wang; Feng Yang; Fan Yang; Yun Li
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-10-06       Impact factor: 1.520

2.  SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer.

Authors:  Dongtao Yin; Yan Jia; Yuanzi Yu; Malcolm V Brock; James G Herman; Chao Han; Xiaomo Su; Yang Liu; Mingzhou Guo
Journal:  Discov Med       Date:  2012-07       Impact factor: 2.970

3.  Influence of Pulmonary Rehabilitation on Lung Function Changes After the Lung Resection for Primary Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Natasa Mujovic; Nebojsa Mujovic; Dragan Subotic; Maja Ercegovac; Andjela Milovanovic; Ljubica Nikcevic; Vladimir Zugic; Dejan Nikolic
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

4.  Lung function changes and complications after lobectomy for lung cancer in septuagenarians.

Authors:  Dragan Subotic; Dragan Mandaric; Gordana Radosavljevic; Jelena Stojsic; Milan Gajic
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

5.  Treatment and survival differences in older Medicare patients with lung cancer as compared with those who are dually eligible for Medicare and Medicaid.

Authors:  Cathy J Bradley; Bassam Dahman; Charles W Given
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

6.  Sublobar resection versus lobectomy in Surgical Treatment of Elderly Patients with early-stage non-small cell lung cancer (STEPS): study protocol for a randomized controlled trial.

Authors:  Fan Yang; Xizhao Sui; Xiuyuan Chen; Lixue Zhang; Xun Wang; Shaodong Wang; Jun Wang
Journal:  Trials       Date:  2016-04-07       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.